NCT03878719View on ClinicalTrials.gov

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

August 19, 2022

Study Completion Date

August 19, 2022

Conditions

Melanoma

Interventions

DRUG

binimetinib

taken orally

DRUG

encorafenib

taken orally

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan

Sponsors

Lead Sponsor

Collaborators (1)

Pierre Fabre Laboratories

All Listed Sponsors

collaborator

Pierre Fabre Laboratories

INDUSTRY

lead

Pfizer

INDUSTRY

NCT03878719 - Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | Biotech Hunter | Biotech Hunter